Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(54)
•••
Comment by HarveyTwofaceon Apr 27, 2020 2:01pm
148 Views
Post# 30958555

RE:RE:RE:RE:silly question?

RE:RE:RE:RE:silly question?Isn't only about delays or so - is about unknown variables. Trying to figure out why some people on this board choose to be blind for some things that matter. Big Pharma will ask about this metabolite before throwing cash on Antibe and paying out of their own pocket for phase III - or they might not care about this "problem" (because they don´t think it is a problem, like some of you seem to do here)... What do you think? Or does everyone here think like you? I am invested but definitely worry about this. Why shouldn't I worry until I have all the facts?

Some of you consider yourselves as extra clever - why dont you educate me and the rest of the board about this, please. I'd like to know more than I already do (which is far from everything, like if this metabolite is gonna cause problems in the long run for those chewing ATB-346 once it is on the market).
I think Dan and Wallace should discuss it more if they know it is safe over time (and not only during two weeks of use in their trials). 

I am hoping for more facts from Dan/Wallace about this (if they have it) so they don´t have to conduct a "phase 2 c" study solely for this metabolite before going for a phase III.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities